- Ownership
- Activity
GSK Stock Ownership Activity
GLAXOSMITHKLINE PLC-SPON ADR 13F holders
No value investing guru has made any change to the GLAXOSMITHKLINE PLC-SPON ADR (GSK) position according to the gurus' latest SEC quarterly report(s).
Which gurus or hedge funds are buying GSK now?
According to the latest SEC filing(s) GLAXOSMITHKLINE PLC-SPON ADR (GSK) has not been purchased by any super investor.
To see more about who is investing in GLAXOSMITHKLINE PLC-SPON ADR (GSK), please go to the GSK ownership page.
2025 Q2
(1 result)
Reported price*: $38.74
2025 Q1
(1 result)
Reported price*: $38.74
2024 Q4
(1 result)
Reported price*: $33.82
2024 Q3
(1 result)
Reported price*: $40.88
2024 Q2
(1 result)
Reported price*: $38.50
2024 Q1
(1 result)
Reported price*: $42.87
2023 Q4
(1 result)
Reported price*: $37.06
2023 Q3
(1 result)
Reported price*: $36.25
2023 Q2
(1 result)
Reported price*: $35.64
2023 Q1
(1 result)
Reported price*: $35.58
2022 Q4
(2 results)
AVG reported price*: $35.14
2022 Q3
(4 results)
AVG reported price*: $29.43
2022 Q2
(4 results)
AVG reported price*: $54.41
2022 Q1
(3 results)
AVG reported price*: $54.45
2021 Q4
(5 results)
AVG reported price*: $55.13
2021 Q3
(3 results)
AVG reported price*: $47.76
2021 Q2
(3 results)
AVG reported price*: $49.78
2021 Q1
(4 results)
AVG reported price*: $44.61
2020 Q4
(4 results)
AVG reported price*: $46.00
2020 Q3
(3 results)
AVG reported price*: $47.05
2020 Q2
(3 results)
AVG reported price*: $51.07
Shares, change to shares, sold shares - split-adjusted.
Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.
Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.